TABLE 1.
Demographic and Clinical Characteristics Summary of OxyContin and Primary Comparator Opioid Use in the Medicaid, MarketScan and HIRD Databases
| Any OxyContin Use* | Any Primary Comparator Opioid Use† | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Value | Medicaid | MarketScan | HIRD | Medicaid | MarketScan | HIRD |
| Patients | 94,445 | 122,254 | 81,137 | 367,814 | 181,240 | 110,619 | |
| Total person-time per patient in months | Mean (SD) | 7.8 (10.0) | 6.0 (10.3) | 6.1 (11.4) | 8.1 (10.3) | 8.0 (11.9) | 9.5 (13.9) |
| Treatment episodes | 522,775 | 561,703 | 378,441 | 2,039,232 | 975,389 | 654,462 | |
| Sex, n (%) | Female | 295,875 (56.6) | 285,366 (50.8) | 189,986 (50.2) | 1,241,520 (60.9) | 560,051 (57.4) | 382,769 (58.5) |
| Male | 226,900 (43.4) | 276,337 (49.2) | 188,455 (49.8) | 797,712 (39.1) | 415,338 (42.6) | 271,693 (41.5) | |
| Age (y) | Mean (SD) | 46.7 (10.5) | 53.1 (12.0) | 51.4 (12.2) | 46.9 (10.6) | 54.6 (11.6) | 53.4 (11.9) |
| DCI | Mean (SD) | 2.0 (2.8) | 2.0 (3.1) | 1.7 (2.8) | 2.0 (2.8) | 2.4 (3.3) | 2.0 (3.0) |
| Comparator use, any, n (%) | ER morphine | 0 | 0 | 0 | 964, 343 (47.3) | 383,442 (39.3) | 252, 960 (38.7) |
| TD fentanyl | 0 | 0 | 0 | 564,161 (27.7) | 441,383 (45.3) | 272,898 (41.7) | |
| Methadone | 0 | 0 | 0 | 510,728 (25.1) | 150,564 (15.4) | 128,604 (19.7) | |
| IR oxycodone | 133,497 (25.5) | 148, 267 (26.4) | 96,452 (25.5) | 290,641 (14.3) | 122,702 (12.6) | 89,639 (13.7) | |
| IR hydromorphone | 29, 378 (5.6) | 24,217 (4.3) | 17,397 (4.6) | 137,657 (6.8) | 67,264 (6.9) | 46,086 (7.0) | |
| ER oxymorphone | 4,937 (0.9) | 5,769 (1.0) | 3,602 (1.0) | 14,035 (0.7) | 10,630 (1.1) | 6,200 (0.9) | |
| Other opioid use (nonprimary/secondary comparators | 210,501 (40.3) | 229,127 (40.8) | 153,387 (40.5) | 924,121 (45.3) | 451,161 (46.3) | 290,985 (44.5) | |
| Clinical and co-morbidity characteristics‡ | Abdominal pain | 99,797 (19.1) | 80,535 (14.3) | 55,554 (14.7) | 436,472 (21.4) | 179,919 (18.4) | 120,612 (18.4) |
| Chronic pain | 104,311 (20.0) | 65,463 (11.7) | 63,456 (16.8) | 427,644 (21.0) | 143,661 (14.7) | 138,170 (21.1) | |
| Neuropathic pain | 16,857 (3.2) | 14,164 (2.5) | 10,627 (2.8) | 70,734 (3.5) | 32,678 (3.4) | 26,043 (4.0) | |
| COPD | 102,942 (19.7) | 64,556 (11.5) | 49,926 (13.2) | 401,863 (19.7) | 129,161 (13.2) | 104,775 (16.0) | |
| Major depression disorder | 88,372 (16.9) | 62,556 (11.1) | 58,692 (15.5) | 378,331 (18.6) | 128,661 (13.2) | 119,470 (18.3) | |
| History of overdose | 2657 (0.5) | 1428 (0.3) | 1110 (0.3) | 15,485 (0.8) | 3801 (0.4) | 3160 (0.5) | |
| Opioid type dependence | 30,472 (5.8) | 9560 (1.7) | 11,343 (3.0) | 119,537 (5.9) | 18,777 (1.9) | 23,706 (3.6) | |
| Nonopioid drug dependence | 32,589 (6.2) | 7963 (1.4) | 8840 (2.3) | 119,625 (5.9) | 15,083 (1.5) | 19,215 (2.9) | |
| Benzodiazepines‡ | 97,110 (18.6) | 86,631 (15.4) | 60,818 (16.1) | 368,051 (18.1) | 154,579 (15.8) | 109,074 (16.7) | |
Frequency (percent) presented unless otherwise specified.
Any use of OxyContin excluding concomitant primary comparator opioid use.
Any use of any of the primary comparators (ER morphine, TD fentanyl, or methadone) excluding concomitant OxyContin or other primary comparator use.
Each of the clinical and co-morbidity characteristics listed used a 3-month lookback period before each treatment episode for their calculation, except for the comparator use, other opioid use and benzodiazepines which were measured during the treatment episodes.
COPD indicates chronic obstructive pulmonary disease; DCI, Deyo-Charlson Index; ER, extended release; HIRD, HealthCore Integrated Research Database; IR, immediate release; TD, transdermal.